- Home
- LPAA vs CMPS Comparison
LPAA vs CMPS Comparison
Compare LPAA & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | CMPS |
|---|---|---|
| Founded | 2024 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | 166 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.3M | 646.2M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPAA | CMPS |
|---|---|---|
| Price | $10.60 | $6.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.43 |
| AVG Volume (30 Days) | 64.5K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.04 | $2.25 |
| 52 Week High | $10.70 | $7.15 |
Technical Indicators
Market Signals| Indicator | LPAA | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 59.63 |
| Support Level | $10.57 | $6.56 |
| Resistance Level | $10.62 | $7.15 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 50.00 | 59.35 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.